Multiple Endocrine Neoplasia Type 2A in an Iranian Family: Clinical and Genetic Studies

Ali Asghar Ghazi MD1, Mahmoud Bagheri MD2, Ali Tabibi MD3, Farzaneh Sarvghadi MD4, Hengameh Abdi MD5, Mehdi Hedayati PhD6, Marina Pourafkari MD4, Farrokh Tirgari MD5, Run Yu MD PhD6

Abstract

Multiple endocrine neoplasia (MEN) type 2A, a dominant inherited syndrome caused by germline activating mutations in the RET proto-oncogene, is characterized by association of medullary thyroid carcinoma, pheochromocytoma and primary hyperparathyroidism. There is limited data on this disease in the Middle East region. In this paper, we present clinical and genetic studies of an Iranian patient and her family members. The patient was a 49-year-old Iranian woman who presented with hypertension due to bilateral pheochromocytoma. She had history of a medullary carcinoma of thyroid which had been operated 28 years ago. Analysis of the RET gene in the family revealed a Cys634Arg mutation in codon 11 and 3 polymorphisms, G691S, S836S and S904S in codons 11, 14 and 15, respectively, that might have been important in modifying the clinical picture. Due to paucity of information on MEN type 2 in the area, this study can be helpful in portraying the clinical and cytogenetic characteristics of the disease in the region.

Keywords: genetic polymorphism, MEN2A, RET mutation

Case Report

A 49-year-old woman was referred to us for evaluation of palpitation, profuse sweating and attacks of severe headache. Her past medical history was significant for a total thyroidectomy when she was 21 years old that was histopathologically proved to be a 5 × 2 cm medullary thyroid carcinoma and attacks of severe hypertension up to 210/140 mmHg during the last 1.5 years. Laboratory evaluations for hypertension disclosed high urine catecholamine metabolites, normal calcitonin, high serum PTH, negative MIBG scan of adrenals and bilateral adrenal tumors. She ignored further evaluation and used only amlodipine and metoprolol to control the symptoms. She was a professional mountaineer and had climbed successfully the Kilimanjaro Peak in Africa and Mont Blanc in Europe during this period despite palpitations and blood pressure of around 180/115 mmHg.

On examination, her heart rate was 105 per minute and her blood pressure was 190/95 mmHg. The rest of physical examination was unremarkable. The laboratory data on admission is shown in Table 1. A computed tomography (CT) scan of the abdomen revealed bilateral suprarenal masses approximately 5 × 3 cm in size with soft tissue consistency (Figure 1). Bilateral pheochromocytoma was suspected based on the patient’s history, laboratory data and radiologic findings. After controlling hypertension with phenoxybenzamine and propranolol, the patient underwent bilateral transperitoneal laparoscopic adrenalectomy through lateral approach, first for the right side and then for the left side in one session. The completely excised tumors measured 6 × 4.5 × 2.5 cm each. Cut sections revealed 2 lobulated brownish tumors, surrounded by adrenal tissue. Microscopic examination revealed pheochromocytoma. Immunohistochemistry (IHC) evaluation showed positivity for chromogranin, synaptophysin and S 100. Ki 67 was estimated as 1%. IHC was negative for CKAE1 and...
Sequencing of the RET proto-oncogene was completed at the Research Institute for Endocrine Sciences affiliated with Shahid Beheshti University of Medical Sciences, Tehran, Iran. The study showed Cys634Arg mutation and 3 polymorphisms; Gly691Ser, Ser836 Ser and Ser904 Ser (Figure 2).

The post-operative course was uneventful and the patient’s hypertension and palpitation disappeared after surgery. One week after surgery, urine catecholamine metabolites and serum calcium were within normal limits but serum PTH was still high. One year after surgery, the patient was examined again. She was normotensive (120/80 mmHg) and did not suffer from palpitation or headache. The patient’s post-operative laboratory data is shown in Table 2. The patient’s family, her mother, her son, two brothers and two sisters were clinically evaluated and also underwent cytogenetic study. There were no clinical findings in favor of MEN 2A in the family. The family’s pedigree and results of biochemical evaluation of the family members are shown in Figure 3 and Table 3, respectively.

Discussion

In this paper, we present for the first time the clinical, laboratory and cytogenetic characteristics of an Iranian patient with MEN 2A harboring Cys634Arg mutation and 3 polymorphisms. The data of her first degree relatives are also presented.

The syndrome of multiple endocrine neoplasia is a rare autosomal dominant disorder with a prevalence of 2.5/100,000 population. It was introduced to medical literature in 1961 and subsequently shown to comprise 3 forms: MEN 2A, MEN 2B and familial MTC (FMTC). MEN 2A is the most prevalent form and presents with MTC in 95% of cases, bilateral pheochromocytoma in 50% of the cases and primary hyperparathyroidism in 25% of cases.5,6

In 1993, a linkage was shown between the syndrome and gain of function mutations in RET gene, which encodes for a ligand dependent membrane receptor with tyrosine kinase activity regulating cell growth and differentiation.5,6 Naturally, the receptor is activated by a complex generated from glial derived neurotropic...
**Table 3.** Laboratory characteristics of the patient’s family; abnormal values are in bold

<table>
<thead>
<tr>
<th></th>
<th>Brother 1</th>
<th>Brother 2</th>
<th>Sister 1</th>
<th>Sister 2</th>
<th>Son</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RET analysis</strong></td>
<td>G691S/S904S</td>
<td>-</td>
<td>S836S</td>
<td>-</td>
<td>G691S/S904S/S836S</td>
<td>-</td>
</tr>
<tr>
<td>Serum calcium (mg/dl)</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10.3</td>
<td><strong>10.4</strong></td>
<td>8.6–10.3</td>
</tr>
<tr>
<td>Serum phosphorus (mg/dl)</td>
<td>3.8</td>
<td>4.4</td>
<td>4.3</td>
<td>4.9</td>
<td>5.0</td>
<td>2.5–4.5</td>
</tr>
<tr>
<td>Serum iPTH (pg/ml)</td>
<td>25</td>
<td>43</td>
<td>31</td>
<td>56</td>
<td>37</td>
<td>15–65</td>
</tr>
<tr>
<td>Serum calcitonin (pg/ml)</td>
<td>3.7</td>
<td>1.8</td>
<td>1.4</td>
<td>2.3</td>
<td>2.5</td>
<td>0.4–11.8</td>
</tr>
<tr>
<td>CEA (pg/ml)</td>
<td>2.0</td>
<td>2.0</td>
<td>0.6</td>
<td>2.7</td>
<td>1.8</td>
<td>Up to 4</td>
</tr>
<tr>
<td>Urine metanephrine (μg/24h)</td>
<td>338</td>
<td>434</td>
<td>79</td>
<td>124</td>
<td>309</td>
<td>Up to 350</td>
</tr>
<tr>
<td>Urine normetanephrine(μg/24h)</td>
<td>17.5</td>
<td>63</td>
<td>31</td>
<td>63</td>
<td>65</td>
<td>14–80</td>
</tr>
</tbody>
</table>

iPTH: Intact parathormone; CEA: Carcinoembryonic antigen

**Figure 2.** Cytogenetic data of the patient
factor (GDNF) ligands and a co-receptor that leads to autophosphorylation and intracellular signaling. With mutant genes, there happens a state of repetitive stimulation with increased intracellular phosphorylation that eventually leads to hyperplasia and tumor formation. It was subsequently shown that each type of MEN2 syndrome is the result of a specific mutation in the RET gene and it was also shown that mutations have different effects on cellular function and behavior. As a rule, mutations that cause more profound derangements in the receptor function lead to development of tumors that are more malignant and appear at an earlier age. The findings gave rise to the concept that there is a strong correlation between phenotype (clinical presentation) and genotype (gene characteristics) of the disease. The discoveries led to application of more accurate cytogenetic technics for diagnosis of affected family members in subclinical stages and paved the way for implementation of prophylactic measures such as thyroidectomy for elimination of the disease in carriers of defective genes.1,9

A mutation at codon 634, located in exon 11, is seen in 85% of patients with MEN 2A and substitution of Arginine for Cysteine, C634 R, is the most common one.1,3,10 Most patients with MEN 2A who present with PHEO or PHPT also harbor C634R mutation. Our patient is likely to have inherited the mutation from her deceased father.

As mentioned earlier, different mutations lead to tumors with different behaviors. According to the guideline of the American Thyroid Association (ATA), these mutations can be divided into 4 categories (A to D) based on the aggressiveness of the corresponding tumors and age at which tumors become clinically evident. According to this classification, mutations in category A lead to tumors that appear in later life and have more benign behavior while mutations in category D appear early in life and have poorer prognosis. Based on these data, codon 634 is in category C.

MTC develops in almost all patients with C634R mutation and is usually the first manifestation. In contrast to sporadic MTC which appears in the fifth decade of life, those who harbor C634R mutation have been reported to have the tumor even before the age of 5 years.11 The RET screening program has improved the prognosis of MTC dramatically. While the 5-year survival of clinically detected MTC is about 50%, those diagnosed through RET sequencing have a cure rate of around 94%. A major factor in this improvement is detection of tumors at an early stage.12 It was thus recommended that all patients with MTC should be evaluated for RET mutations and those harboring C634R mutation should undergo prophylactic thyroidectomy before the age of 5 years.6 The clinical course of the disease in our patient is somehow unusual. While most patients with clinically detectable tumors have cervical lymph node metastasis and elevation of calcitonin post-surgically, she had normal calcitonin levels 20 years after surgery. Pheochromocytoma develops in approximately 50% of patients with MEN 2A. A recent study from Japan showed that penetrance of PHEO is 25% by 30 years of age, 52% by 50 years of age and 88% by 77 years of age in carriers of mutations in codon 634.13 The tumor is always intra-adrenal, may appear bilaterally and have benign nature in the majority of cases. It can appear before, during or after development of MTC in patients with mutation in codon 634.6,14

Primary hyperparathyroidism is seen in 15% – 25% of patients. In most cases, the diagnosis of the disease is synchronous with that of MTC. It is clinically asymptomatic in 80% of cases and is usually diagnosed with mild elevation of serum calcium and mild to moderate elevation of serum PTH. There can be a spectrum of histopathologic abnormalities, ranging from single adenoma, dou-
ble adenoma or hyperplasia in four glands.\textsuperscript{15} Our patient had no symptoms attributable to PHPT and based on the calcium level, we preferred to follow the patient annually.

The pathogenic significance of polymorphisms is not well known. There are studies both in favor of and against the contributing role of polymorphisms or variants of unknown significance in tumor genesis.\textsuperscript{2,16} In the 2 synonymous polymorphisms of our patient, S\textsuperscript{691}S and S\textsuperscript{836}S, since there is no change in the amino acid sequence, it seems that there should be no change in the functional ability of the corresponding protein. This assumption cannot be the case in the G\textsuperscript{691}S variant where the polar serine substitutes for the neutral glycine; a change that might have detrimental effects on functional characteristics of the receptor. However, Fugazzola et al demonstrated that this variant had no effect on functional activity of the tyrosine receptor.\textsuperscript{17}

In this paper, we have demonstrated the clinical, biochemical and laboratory manifestations of an Iranian family with complete features of MEN 2A. The case is somehow unusual for benign behavior of a clinically evident MTC for about 30 years and occurrence of 3 polymorphisms that might have had contributing effects on the tumor characteristics. Further studies are needed to evaluate the findings in a sufficient number of patients in order to portray a more accurate picture of the disease in the region.

Acknowledgments

The authors would like to express their appreciation and gratitude to family members for their cooperation and Ms. Marjan Zarif Yeganeh for her excellent laboratory assistance.

Declaration of Conflicting Interests

None of the authors had any personal or financial conflicts of interest.

References

1. Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple endocrine neoplasia type 2. \textit{Clinics (Sao Paulo)}. 2012; \textbf{67 (suppl 1)}: 69 – 75.